示踪剂在乳腺癌前哨淋巴结活检中的临床应用

doi:10.3760/cma.j.issn.1673-422X.2018.04.014

摘要/Abstract

摘要： 乳腺癌的治疗越来越个体化及微创化，前哨淋巴结活检术成为了临床腋窝淋巴结阴性早期乳腺癌患者腋窝的标准处理方式。示踪剂将前哨淋巴结或淋巴管显像，便于前哨淋巴结活检术的顺利开展。示踪剂的选择也愈来愈多样化，如纳米炭混悬液、亚甲蓝、放射性同位素、吲哚菁绿等。不同示踪剂及联合应用各有其优势与局限，示踪方式的选择还需权衡多方面的因素。

关键词: 乳腺肿瘤, 前哨淋巴结活检术, 示踪剂

Abstract: The treatment of breast cancer is becoming more individualized and minimally invasive, which makes sentinel lymph node biopsy becoming the standard treatment for axillary in patients with early-stage breast cancer who are negative in clinical axillary lymph nodes. Tracers image sentinel lymph nodes or lymphatic vessels for the successful detection of sentinel lymph node biopsy. Tracers selection is also more diverse, such as nano carbon mixed suspension, methylene blue, radioisotope, indocyanine green, etc. Different tracers and combined applications have their advantages and limitations. As for the selection of tracing methods, many factors need to be weighed.

Key words: Breast neoplasms, Sentinel lymph node biopsy, Tracer

史曼曼,陈创,李智宇,孙圣荣. 示踪剂在乳腺癌前哨淋巴结活检中的临床应用[J]. 国际肿瘤学杂志, 2018, 45(4): 245-249.

Shi Manman, Chen Chuang, Li Zhiyu, Sun Shengrong. Tracers′ clinical application status in the sentinel lymph node biopsy of breast cancer[J]. Journal of International Oncology, 2018, 45(4): 245-249.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillarylymphnode dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B32 randomised phase 3 trial［J］. Lancet Oncol, 2010, 11(10): 927-933. DOI: 10.1016/S1470-2045(10)702072. ［3］ Tvedskov TF. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection［J］. Dan Med J, 2012, 59(7): B4475. ［4］赵丽娟, 张晓红, 张珍, 等. 乳癌改良根治术前纳米炭注射时机的对比研究［J］. 四川医学, 2016, 37(6): 609-612. DOI: 10.16252/j.cnki.issn1004-0501-2016.06.009. ［5］张永松, 梁全琨, 钟玲, 等. 纳米炭和亚甲蓝联合核素示踪法在腔镜乳腺癌前哨淋巴结活组织检查中的对照研究［J］. 中华乳腺病杂志(电子版), 2015, 9(4): 231-235. DOI: 10.3877/cma.j.issn.1674-0807.2015.04.002. ［6］陈智, 覃庆洪, 练斌, 等. 纳米炭混悬液与美蓝在乳腺癌前哨淋巴结活检中的应用研究［J］. 实用癌症杂志, 2015, 30(9): 1320-1323. DOI: 10.3969/j.issn.1001-5930.2015.09.017. ［7］林启谋, 周毅, 李勇, 等. 纳米碳乳腺癌前哨淋巴结活检中的应用研究［J］. 吉林医学, 2012, 33(26): 5616-5617. ［8］范林军, 钟玲, 郭德玉, 等. 纳米炭对乳腺癌腋窝淋巴结示踪效果及其安全性的初步研究［J］. 中华乳腺病杂志(电子版), 2010, 4(3): 47-50. DOI: 10.3969/j.issn.1674-0807.2010.03.012. ［9］ Peek MC, Charalampoudis P, Anninga BA, et al. Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and metaanalysis［J］. Future Oncol, 2017, 13(5): 455-467. DOI: 10.2217/fon-2016-0255. ［10］ Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer［J］. Ann Surg, 1994, 220(3): 391-401. ［11］ Varghese P, AbdelRahman AT, Akberali S, et al. Methylene blue dye—a safe and effective alternative for sentinel lymph node localization［J］. Breast J, 2008, 14(1): 61-67. DOI: 10.1111/j.15244741.2007.00519.x. ［12］ Bakhtiar N, Jaleel F, Moosa FA, et al. Sentinel lymph node identification by blue dye in patients with breast carcinoma［J］. Pak J Med Sci, 2016, 32(2): 448-451. DOI: 10.12669/pjms.322.9563. ［13］ Ang CH, Tan MY, Teo C, et al. Blue dye is sufficient for sentinel lymph node biopsy in breast cancer［J］. Br J Surg, 2014, 101(4): 383-389. DOI: 10.1002/bjs.9390. ［14］ Fattahi AS, Tavassoli A, Rohbakhshfar O, et al. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery?［J］. J Res Med Sci, 2014, 19(10): 918-922. ［15］ He PS, Li F, Li GH, et al. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review［J］. BMC Cancer, 2016, 16(1): 107-119. DOI: 10.1186/s12885-016-2137-0. ［16］ Guo W, Zhang L, Ji J, et al. Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer［J］. World J Surg Oncol, 2014, 12: 290. DOI: 10.1186/1477-7819-12-290. ［17］王新华, 古力努尔·哈布力哈吉, 董占飞, 等. 99mTc硫胶体术前淋巴显像在乳腺癌前哨淋巴结活检中的应用［J］. 中国肿瘤临床, 2010, 37(21): 1227-1231. DOI: 10.3969/j.issn.1000-8179.2010.21.007. ［18］刘娟娟，孙晓，王春英，等. 乳腺癌前哨淋巴结活检术前淋巴显像的临床意义［J］. 山东医药, 2012, 52(5): 78-79. DOI: 10.3969/j.issn.1002-266X.2012.05.035. ［19］乔江华, 焦得闯, 卢振铎, 等. 术前淋巴结显像在乳腺癌前哨淋巴结活检中的应用价值［J］. 中国肿瘤, 2014, 23(4): 346-348. DOI: 10.11735/j.issn.1004-0242.2014.04.A016. ［20］ Serrano-Vicente J, Rayo-Madrid JI, Dominguez-Grande ML, et al. Role of SPECT-CT in breast cancer sentinel node biopsy when internal mammary chain drainage is observed［J］. Clin Transl Oncol, 2016, 18(4): 418-425. DOI: 10.1007/s12094-015-1384-x. ［21］ Niebling MG, Pleijhuis RG, Bastiaannet E, et al. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping［J］. Eur J Surg Oncol, 2016, 42(4): 466-473. DOI: 10.1016/j.ejso.2015.12.007. ［22］刘琳, 张保宁, 杨红鹰, 等. 核素淋巴显像识别前哨淋巴结在乳腺癌治疗中的应用［J］. 中华乳腺病杂志(电子版), 2010, 4(3): 14-18. DOI: 10.3969/j.issn.1674-0807.2010.03.005. ［23］中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)［J］. 中国癌症杂志, 2015, 25(09): 692-754. DOI: 10.3969/j.issn.1007-3696.2015.09.010. ［24］ Kitai T, Inomoto T, Miwa M, et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer［J］. Breast Cancer, 2005, 12(3): 211-215. ［25］ Inoue T, Nishi T, Nakano Y, et al. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer［J］. Breast Cancer, 2016, 23(2): 295-300. DOI: 10.1007/s12282-014-0573-8. ［26］杨金梅, 崔莉青, 李雪. 吲哚菁绿脉管成像仪系统在乳腺癌术中前哨淋巴结活检中的应用［J］. 护理研究, 2016, 30(10): 1267-1268. DOI: 10.3969/j.issn.1009-6493.2016.10.037. ［27］ Sugie T, Kassim KA, Takeuchi M, et al. A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer［J］. Cancers (Basel), 2010, 2(2): 713-720. DOI: 10.3390/cancers2020713. ［28］ Sugie T, Sawada T, Tagaya N, et al. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in earlystage breast cancer［J］. Ann Surg Oncol, 2013, 20(7): 2213-2218. DOI: 10.1245/s10434-013-2890-0. ［29］ Hirche C, Murawa D, Mohr Z, et al. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer［J］. Breast Cancer Res Treat, 2010, 121(2): 373-378. DOI: 10.1007/s10549-010-0760-z. ［30］邹伟伟, 白玉, 王希龙, 等. 吲哚菁绿与纳米碳在乳腺癌前哨淋巴结活检中的对比研究［J］. 中国普通外科杂志, 2016, 25(11): 1627-1632. DOI: 10.3978/j.issn.1005-6947.2016.11.018. ［31］ Hunt KK, Ballman KV, Mccall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection results of the ACOSOG Z0010 trial［J］. Ann Surg, 2012, 256(3): 428-436. DOI: 10.1097/SLA.0b013e3182654494. ［32］ Hirano A, Kamimura M, Ogura K, et al. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients［J］. Ann Surg Oncol, 2012, 19(13): 4112-4116. DOI: 10.1245/s10434-012-2478-0. ［33］ Cong BB, Sun X, Song XR, et al. Preparation study of indocyanine greenrituximab: a new receptortargeted tracer for sentinel lymph node in breast cancer［J］. Oncotarget, 2016, 7(30): 47526-47535. DOI: 10.18632/oncotarget.10204. ［34］田崇麟, 孙晓, 刘雁冰, 等. 乳腺癌前哨淋巴结活检术新型示踪剂的动物模型研究［J］. 中国癌症杂志, 2016, 26(7): 569-573. DOI: 10.19401/j.cnki.1007-3639.2016.07.002. ［35］孔之华, 黄义方, 李娟娟, 等. 纳米炭与亚甲蓝示踪剂在乳腺癌腋窝前哨淋巴结活检中应用效果比较［J］. 广西医学, 2016, 38(6): 852-853, 858. DOI: 10.11675/j.issn.0253-4304.2016.06.28. ［36］邵志敏, 李俊杰. 2015版《中国抗癌协会乳腺癌诊治指南与规范》:外科部分解读［J］. 中华乳腺病杂志(电子版), 2016, 10(1): 1-5. DOI: 10.3877/cma.j.issn.1674-0807.2016.01.001. ［37］李艺, 王燕, 常婷, 等. 经皮超声造影提示前哨淋巴结性质对腋窝淋巴结良恶性评估的价值［J］. 上海交通大学学报(医学版), 2015, 35(9): 1320-1324. DOI: 10.3969/j.issn.1674-8115.2015.09.015. ［38］应海岳, 吴海涛. CT间接淋巴造影诊断舌癌颈淋巴结早期转移［J］. 温州医科大学学报, 2016, 46(9): 660-665. DOI: 10.3969/j.issn.2095-9400.2016.09.009. ［39］ Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the falsenegative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance)［J］. Ann Surg, 2016, 263(4): 802-807. DOI: 10.1097/SLA.0000000000001375. ［40］ Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients［J］. Ann Surg Oncol, 2015, 22(2): 377-382. DOI: 10.1245/s10434-014-4034-6. ［41］ Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with NodePositive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection［J］. J Clin Oncol, 2016, 34(10): 1072-1078. DOI: 10.1200/JCO.2015.64.0094. ［42］王丽娜, 李德良, 张南, 等. 淋巴靶向造影剂的研究进展［J］. 中国海洋药物, 2016, 35(2): 95-102. DOI: 10.13400/j.cnki.cjmd.2016.02.015. ［43］ Kim SH, Oh SN, Choi HS, et al. USPIO enhanced lymph node MRI using 3D multi-echo GRE in a rabbit model［J］. Contrast Media Mol Imaging, 2016, 11(6): 544549. DOI: 10.1002/cmmi.1716. ［44］郑红梅, 陈创, 吴新红, 等. 量子点标记探针技术在乳腺癌中的应用进展［J］. 武汉大学学报(医学版), 2015, 36(3): 399-403. DOI: 10.14188/j.1671-8852.2015.03.017. ［45］ Alam F, Yadav N. Potential applications of quantum dots in mapping sentinel lymph node and detection of micrometastases in breast carcinoma［J］. J Breast Cancer, 2013, 16(1): 1-11. DOI: 10.4048/jbc.2013.16.1.1.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.